Climb Bio (NASDAQ:CLYM - Get Free Report) had its price objective increased by BTIG Research from $8.00 to $19.00 in a research note issued on Wednesday,Benzinga reports. The firm currently has a "buy" rating on the stock. BTIG Research's target price points to a potential upside of 65.94% from the stock's previous close.
Several other brokerages have also weighed in on CLYM. Weiss Ratings reiterated a "sell (d-)" rating on shares of Climb Bio in a research report on Monday, April 20th. Mizuho began coverage on shares of Climb Bio in a research report on Wednesday, April 15th. They set an "outperform" rating and a $18.00 target price on the stock. Piper Sandler began coverage on shares of Climb Bio in a research report on Friday, February 13th. They set an "overweight" rating on the stock. Oppenheimer lifted their target price on shares of Climb Bio from $10.00 to $18.00 and gave the company an "outperform" rating in a research report on Tuesday, April 21st. Finally, Raymond James Financial began coverage on shares of Climb Bio in a research report on Tuesday, March 10th. They set a "strong-buy" rating and a $25.00 target price on the stock. Three investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $18.40.
Check Out Our Latest Stock Report on Climb Bio
Climb Bio Price Performance
NASDAQ CLYM opened at $11.45 on Wednesday. The firm has a market capitalization of $546.97 million, a price-to-earnings ratio of -12.87 and a beta of 0.02. The company's fifty day moving average is $7.66 and its two-hundred day moving average is $4.93. Climb Bio has a 52-week low of $1.13 and a 52-week high of $11.49.
Climb Bio (NASDAQ:CLYM - Get Free Report) last posted its quarterly earnings results on Thursday, March 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.06). As a group, sell-side analysts expect that Climb Bio will post -1.11 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Climb Bio
Institutional investors have recently added to or reduced their stakes in the company. AQR Capital Management LLC bought a new position in Climb Bio during the 1st quarter valued at about $27,000. Vanguard Personalized Indexing Management LLC bought a new position in shares of Climb Bio in the third quarter worth about $29,000. Qube Research & Technologies Ltd bought a new position in shares of Climb Bio in the second quarter worth about $43,000. Virtu Financial LLC bought a new position in shares of Climb Bio in the fourth quarter worth about $43,000. Finally, Blair William & Co. IL bought a new position in shares of Climb Bio in the fourth quarter worth about $44,000. 69.76% of the stock is owned by institutional investors.
About Climb Bio
(
Get Free Report)
Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company's mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.
At the heart of Climb Bio's approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Climb Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Climb Bio wasn't on the list.
While Climb Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
